S. Sean Tu

1.4k total citations
63 papers, 1.1k citations indexed

About

S. Sean Tu is a scholar working on Economics and Econometrics, Management of Technology and Innovation and Immunology. According to data from OpenAlex, S. Sean Tu has authored 63 papers receiving a total of 1.1k indexed citations (citations by other indexed papers that have themselves been cited), including 32 papers in Economics and Econometrics, 23 papers in Management of Technology and Innovation and 11 papers in Immunology. Recurrent topics in S. Sean Tu's work include Pharmaceutical Economics and Policy (29 papers), Intellectual Property and Patents (23 papers) and Health Systems, Economic Evaluations, Quality of Life (13 papers). S. Sean Tu is often cited by papers focused on Pharmaceutical Economics and Policy (29 papers), Intellectual Property and Patents (23 papers) and Health Systems, Economic Evaluations, Quality of Life (13 papers). S. Sean Tu collaborates with scholars based in United States, Canada and United Kingdom. S. Sean Tu's co-authors include Richard A. Cerione, Wen Jin Wu, Helen M. Beere, Douglas R. Green, Gary L. Johnson, Ryan Oyer, Spencer B. Gibson, Steven M. Anderson, Gavin P. McStay and Louis-Martin Boucher and has published in prestigious journals such as New England Journal of Medicine, Cell and Proceedings of the National Academy of Sciences.

In The Last Decade

S. Sean Tu

51 papers receiving 1.0k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
S. Sean Tu United States	9	714	225	188	137	90	63	1.1k
Jason Clark United States	16	311 0.4×	125 0.6×	645 3.4×	271 2.0×	39 0.4×	29	1.2k
Andrea Mohr Ireland	21	839 1.2×	71 0.3×	318 1.7×	214 1.6×	16 0.2×	30	1.2k
Kerstin Müller Germany	15	237 0.3×	46 0.2×	115 0.6×	149 1.1×	51 0.6×	25	717
Stacey J. Adam United States	15	636 0.9×	101 0.4×	286 1.5×	79 0.6×	10 0.1×	32	984
Gaia Cantelli United Kingdom	11	419 0.6×	102 0.5×	235 1.3×	132 1.0×	6 0.1×	12	845
Nicole E. Willmarth United States	17	671 0.9×	71 0.3×	496 2.6×	164 1.2×	15 0.2×	23	1.2k
Timothy Eisen United Kingdom	19	1.1k 1.5×	358 1.6×	458 2.4×	166 1.2×	20 0.2×	39	1.9k
Nithya Krishnamurthy United States	9	751 1.1×	52 0.2×	384 2.0×	102 0.7×	15 0.2×	20	1.2k
Tsukasa Igawa Japan	16	481 0.7×	67 0.3×	278 1.5×	97 0.7×	19 0.2×	107	1.2k
Marco Arndt Germany	16	600 0.8×	78 0.3×	607 3.2×	120 0.9×	13 0.1×	37	1.7k

Countries citing papers authored by S. Sean Tu

Since Specialization

Citations

This map shows the geographic impact of S. Sean Tu's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by S. Sean Tu with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites S. Sean Tu more than expected).

Fields of papers citing papers by S. Sean Tu

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by S. Sean Tu. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by S. Sean Tu. The network helps show where S. Sean Tu may publish in the future.

Co-authorship network of co-authors of S. Sean Tu

This figure shows the co-authorship network connecting the top 25 collaborators of S. Sean Tu. A scholar is included among the top collaborators of S. Sean Tu based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with S. Sean Tu. S. Sean Tu is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Hwang, Catherine S. & S. Sean Tu. (2025). Using Trademarks to Ensure Completion of Postapproval Trials. JAMA Health Forum. 6(2). e250001–e250001.

Tu, S. Sean, et al.. (2025). Accelerating biosimilar market access: the case for allowing earlier standing. Journal of Law and the Biosciences. 12(1). lsae030–lsae030. 1 indexed citations

Price, W. Nicholson, et al.. (2025). The puzzle of biologics manufacturing platform patents. Nature Biotechnology. 43(3). 295–299.

Tu, S. Sean, et al.. (2024). Extent of Drug Patents With Terminal Disclaimers and Obviousness-Type Double Patenting Rejections. JAMA. 332(10). 837–837. 1 indexed citations

Tu, S. Sean. (2024). The Long CON: An Empirical Analysis of Pharmaceutical Patent Thickets. University of Pittsburgh Law Review. 86(1). 1 indexed citations

Tu, S. Sean, et al.. (2024). Patent Portfolios Protecting 10 Top-Selling Prescription Drugs. JAMA Internal Medicine. 184(7). 810–810. 5 indexed citations

Tu, S. Sean & William B. Feldman. (2024). Use of Track One Prioritized Examination for Pharmaceutical Patents. JAMA Health Forum. 5(7). e241886–e241886. 1 indexed citations

Kesselheim, Aaron S., et al.. (2024). Delivery Device Patents on GLP-1 Receptor Agonists. JAMA. 331(9). 794–794.

Feldman, William B., et al.. (2023). Manufacturer Revenue on Inhalers After Expiration of Primary Patents, 2000-2021. JAMA. 329(1). 87–87. 11 indexed citations

10.

Tu, S. Sean & Rebecca Tushnet. (2023). Free Speech Challenges to the Inflation Reduction Act. JAMA. 330(13). 1229–1229. 2 indexed citations

11.

Tu, S. Sean, et al.. (2023). Broad Patent Claims Come Before the Supreme Court in Amgen v Sanofi. JAMA. 329(19). 1641–1641. 2 indexed citations

12.

Tu, S. Sean, Rachel W. Goode, & William B. Feldman. (2023). Biologic Patent Thickets and Terminal Disclaimers. JAMA. 331(4). 355–355. 7 indexed citations

13.

Tu, S. Sean, et al.. (2023). Patenting Strategies on Inhaler Delivery Devices. CHEST Journal. 164(2). 450–460. 5 indexed citations

14.

Beall, Reed F., et al.. (2023). Patents and regulatory exclusivities on FDA-approved insulin products: A longitudinal database study, 1986–2019. PLoS Medicine. 20(11). e1004309–e1004309. 7 indexed citations

15.

Tu, S. Sean & Aaron S. Kesselheim. (2023). Preserving Timely Generic Drug Competition with Legislation on “Skinny Labeling”. Clinical Pharmacology & Therapeutics. 115(1). 22–24.

16.

Wouters, Olivier J., William B. Feldman, & S. Sean Tu. (2022). Product Hopping in the Drug Industry — Lessons from Albuterol. New England Journal of Medicine. 387(13). 1153–1156. 8 indexed citations

17.

Tu, S. Sean. (2018). Bigger and Better Patent Examiner Statistics. The Research Repository @ WVU (West Virginia University). 1 indexed citations

18.

Tu, S. Sean. (2015). Understanding the Backlog Problems Associated with Requests for Continued Examination Practice. eYLS (Yale Law School). 13(1). 216–246. 1 indexed citations

19.

Tu, S. Sean. (2015). Invalidated Patents and Associated Patent Examiners. The Research Repository @ WVU (West Virginia University). 1 indexed citations

20.

Tu, S. Sean, et al.. (2010). The road more traveled—common pitfalls on the way to a patent. Wiley Interdisciplinary Reviews Nanomedicine and Nanobiotechnology. 3(1). 1–4. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact